BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Strattera Safety Helped By DNA Testing, According To FDA Approved Product Labeling Notes Genelex Corporation Founder, Howard Coleman


10/19/2005 5:12:58 PM

SEATTLE, March 9 /PRNewswire/ -- Stratterra, was recently approved by the FDA for the treatment of ADHD (attention-deficit/hyperactivity disorder) in children. Strattera's removal from the body is profoundly affected by the genetics of an enzyme called CYP2D6. According to the FDA approved label for Strattera, individuals who are CYP2D6 poor metabolizers because of their DNA, are twice as likely to suffer from adverse side effects. A recent FDA warning adds severe liver damage to the list of side effects that have so far been associated with this drug. Strattera is in a relatively new class of drugs has only been on the market since December 2004 so its long term adverse side effects are not yet known.

"Given the recent release of Strattera, and the profound effect of genetics on it's removal from the body, a prudent and personalized approach to prescribing this medicine should include DNA testing," stated Howard Coleman, founder of Genelex. "The doctors and patients who order DNA testing when bringing a child up on Strattera have a much greater chance of avoiding problems with this potentially very helpful medication," Coleman added.

About 7% of the population are CYP2D6 poor metabolizers and another 35% are easily converted to poor metabolizer status if they are also taking many common medicines including pain relievers, cough syrup, antidepressants, St John's Wort and many heart medicines. The FDA label tells us that poor metabolizers take almost five times as long to eliminate the drug (24 hour half-life as compared to 5 for normal metabolizers) will reach a five times higher peak level in their blood and have an overall ten times greater exposure to Strattera.

Genelex Corporation, Seattle, Washington is a DNA testing laboratory dedicated to bringing the benefits of pharmacogenetic drug reaction testing to patients and their physicians in order to reduce the high levels of morbidity and mortality that result from adverse drug reactions.

Genelex Corporation

CONTACT: Howard Coleman of Genelex Corporation, +1-425-825-2870, orHCColeman@genelex.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES